Praziquantel: Discovery and Development of an Anthelmintic Drug
暫譯: 吡喹酮：一種驅蟲藥的發現與開發

Spangenberg, Thomas

Praziquantel: Discovery and Development of an Anthelmintic Drug
  • 出版商: Springer
  • 出版日期: 2025-10-04
  • 售價: $2,770
  • 貴賓價: 9.5 折 $2,632
  • 語言: 英文
  • 頁數: 253
  • 裝訂: Hardcover - also called cloth, retail trade, or trade
  • ISBN: 3031973968
  • ISBN-13: 9783031973963

    • 海外代購書籍(需單獨結帳)

相關主題

商品描述

This open-access book provides a comprehensive reference on the discovery and development of praziquantel. It presents the full research and development (R&D) journey of this essential anthelmintic drug, combining foundational science with practical insights.

The book covers a wide range of topics, including a brief history of pharmaceutical industry, unmet medical needs, parasitic flatworm biology, and strategies for schistosomiasis control and elimination. Both human and animal health applications are addressed. Additional chapters explore chemical and manufacturing aspects, drug targets, biomarkers, toxicology, clinical efficacy, regulatory pathways, and Intellectual Property considerations. Rich illustrations, expert commentary, and clear summaries enhance the educational value of the text.

Designed for students, academics, and industry professionals alike, this volume serves as a valuable addition to any scientific library. It also supports the United Nations Sustainable Development Goal 3 (Good Health and Well-being) by contributing to the global fight against schistosomiasis and other Neglected Tropical Diseases.

商品描述(中文翻譯)

這本開放存取的書籍提供了關於吡喹酮（praziquantel）發現與開發的全面參考。它呈現了這種重要的驅蟲藥物的完整研究與開發（R&D）過程，結合了基礎科學與實用見解。

本書涵蓋了廣泛的主題，包括製藥產業的簡史、未滿足的醫療需求、寄生性扁蟲生物學，以及控制和消除血吸蟲病的策略。書中同時探討了人類和動物健康的應用。額外的章節探討了化學和製造方面、藥物靶點、生物標記、毒理學、臨床療效、監管途徑以及智慧財產權的考量。豐富的插圖、專家評論和清晰的摘要增強了文本的教育價值。

本書旨在為學生、學者和業界專業人士提供價值，是任何科學圖書館的重要補充。它也支持聯合國可持續發展目標3（良好健康與福祉），為全球對抗血吸蟲病及其他被忽視的熱帶疾病作出貢獻。

作者簡介

Thomas Spangenberg, PhD - With Merck since 2015, Thomas is heading global health research and leads drug discovery programs from drug screening to preclinical candidate nomination. He drives translation research by generating Real-World Data to support clinical candidates and catalyses research in infectious diseases through open innovation initiatives. Prior to joining Merck, Thomas was part of the drug discovery team at non-for-profit R&D organization Medicines for Malaria Venture (Switzerland), where he led the open-source Malaria Box and Pathogen Box initiatives aimed at accelerating drug discovery for infectious diseases.

Thomas holds a PhD in organic chemistry from the Universities of Strasbourg (France) and Freiburg im Breisgau (Germany). In 2009, he became a post-doctoral fellow at Harvard University (USA), contributing to the total synthesis of mycolactones and advancing point-of-care diagnostics for Buruli ulcer, a neglected necrotizing skin disease. He has authored and co-authored over 50 peer-reviewed articles and is a co-inventor on several patents.

作者簡介(中文翻譯)

托馬斯·斯潘根伯格 (Thomas Spangenberg)，博士 - 自2015年以來在默克 (Merck) 工作，托馬斯負責全球健康研究並領導從藥物篩選到臨床前候選藥物提名的藥物發現計劃。他通過生成真實世界數據來推動轉化研究，以支持臨床候選藥物，並通過開放創新計劃促進傳染病研究。在加入默克之前，托馬斯曾是非營利研發組織「抗瘧疾藥物創新基金會」(Medicines for Malaria Venture，瑞士) 的藥物發現團隊成員，並領導開源的「瘧疾盒」(Malaria Box) 和「病原體盒」(Pathogen Box) 計劃，旨在加速傳染病的藥物發現。

托馬斯擁有法國斯特拉斯堡大學 (Universities of Strasbourg) 和德國弗賴堡 (Freiburg im Breisgau) 的有機化學博士學位。2009年，他成為哈佛大學 (Harvard University，美國) 的博士後研究員，參與了分子乳酸酯 (mycolactones) 的全合成，並推進了針對布魯利潰瘍 (Buruli ulcer) 的即時診斷技術，這是一種被忽視的壞死性皮膚疾病。他已發表和共同發表超過50篇同行評審的文章，並在多項專利中擔任共同發明人。

類似商品